Payment overview · 2025
General Payments
$503.06
21 reported records · 7 companies
Healthcare provider profile · identity verified
Nathaniel L Haddock, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JUNEAU, AK · NPI 1659397065
Verified facts
What the public records show
CMS Open Payments records show Nathaniel L Haddock, M.D. received $503.06 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPDIVO as an associated drug or biological on 20448 records involving 6494 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Opdivo by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $152.72 | 30.4% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $109.98 | 21.9% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $58.34 | 11.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $51.20 | 10.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.05 | 10.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.53 | 8.4% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $37.24 | 7.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $503.06 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $95.58 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $76.18 | 4 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $59.24 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $51.20 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $51.05 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $50.74 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $50.74 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.68 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $20.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 191 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
149 | 46 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
191 | 46 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | OPDIVO open payments reported associated product |
CMS Open Payments — General Payments 20448 supporting records · 6494 recipient NPIs · example record 1184377705 |
Opdivo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 670 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 639 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 600 | 165 |
| Metoprolol Succinate | Metoprolol Succinate | 518 | 131 |
| Tamsulosin Hcl | Tamsulosin Hcl | 432 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 73 |
| Lisinopril | Lisinopril | 291 | 73 |
| Simvastatin | Simvastatin | 258 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 216 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 53 |
| Eliquis | Apixaban | 191 | 46 |
| Potassium Chloride | Potassium Chloride | 174 | 46 |
| Jardiance | Empagliflozin | 166 | 37 |
| Farxiga | Dapagliflozin Propanediol | 149 | 46 |
| Ozempic | Semaglutide | 145 | 26 |
| Mounjaro | Tirzepatide | 144 | 18 |
| Finasteride | Finasteride | 143 | 36 |
| Metformin Hcl Er | Metformin Hcl | 135 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 134 | 36 |
| Eplerenone | Eplerenone | 133 | 38 |
| Warfarin Sodium | Warfarin Sodium | 102 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 51 |
| Alendronate Sodium | Alendronate Sodium | 92 | 20 |
| Omeprazole | Omeprazole | 89 | 30 |
| Allopurinol | Allopurinol | 76 | 24 |
| Myrbetriq | Mirabegron | 74 | suppressed |
| Carvedilol | Carvedilol | 73 | 19 |
| Xarelto | Rivaroxaban | 73 | 20 |
| Trazodone Hcl | Trazodone Hcl | 71 | 19 |
| Furosemide | Furosemide | 67 | 24 |
| Gabapentin | Gabapentin | 65 | 18 |
| Spironolactone | Spironolactone | 62 | 17 |
| Torsemide | Torsemide | 60 | 20 |
| Valacyclovir | Valacyclovir Hcl | 52 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 15 |
| Metformin Hcl | Metformin Hcl | 40 | 15 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Tadalafil | Tadalafil | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 22 |
| Potassium Citrate Er | Potassium Citrate | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 33 | 12 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 11 |
| Ramipril | Ramipril | 32 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Azithromycin | Azithromycin | 25 | 19 |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Prednisone | Prednisone | 24 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Wegovy | Semaglutide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Pacerone | Amiodarone Hcl | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Opdivo | Nivolumab | 12 | suppressed |
| Pulmicort Flexhaler | Budesonide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $503.06 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, DUPIXENT, ELIQUIS, ENTRESTO, FARXIGA, LEQVIO, NUCALA, PENMENVY, SHINGRIX, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error